Journal of the National Cancer Institute Advance Access originally published online on March 25, 2008
JNCI Journal of the National Cancer Institute 2008 100(7):451-452; doi:10.1093/jnci/djn074
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press.
|
|
EDITORIALS |
Should Observational Studies Be a Thing of the Past?
Affiliation of author: Division of Medical Oncology, Sunnybrook Odette Cancer Centre, Toronto, ON, Canada
Correspondence to: Kathleen I. Pritchard, MD, FRCPC, Division of Medical Oncology, Sunnybrook Odette Cancer Centre, 2075 Bayview Ave, T2-185, Toronto, ON M4N 3M5, Canada (e-mail: kathy.pritchard{at}sunnybrook.ca).
Holmberg et al. (1) have presented, in this issue of the Journal, updated follow-up on their randomized HABITS (Hormonal Replacement Therapy After Breast Cancer—Is it Safe?) trial of the use of hormone replacement therapy (HRT) in breast cancer survivors. This topic has been extremely controversial. Before the initial publication of the HABITS trial (2), the only available data concerning the use of HRT in breast cancer survivors came from a series of observational studies and clinical case series, the results of which suggested that this practice was safe (3). A small, underpowered randomized trial also provided some reassurance (4).
Now, Holmberg et al.'s (1) follow-up of the HABITS trial suggests quite definitively that there is a statistically significantly increased risk of recurrence in women given HRT following a diagnosis of breast cancer (hazard ratio = 2.4, 95% CI = 1.3 to 4.2). Fewer than 500 randomly assigned patients were required to demonstrate a difference in the incidence of new breast cancer events at 5 years: that is, 22% in the hormone therapy arm vs 8% in the control arm of this trial. Although another study that was completed around the same time, the Stockholm Breast Cancer Study Group Trial (5), does not show as clear an effect, pooled data from the two studies still suggested a harmful effect from the use of HRT. Both the Stockholm and HABITS trials were terminated early because of these safety analyses (6).
Although randomized data concerning use of HRT for symptomatic intervention in breast cancer survivors are still sparse, it seems that the harmful side effects of HRT have finally been clearly demonstrated in what is, by today's standards, a small randomized trial, carried out in a few relatively small countries. Why did we wait so long?
The controversy in this area parallels a larger controversy relating to the use of HRT in healthy women. During the same time period that the HABITS trial was ongoing, a randomized trial designed to measure the overall health effects of HRT using estrogen alone in hysterectomized women and estrogen plus progesterone in women with an intact uterus was finally being carried out (7). This trial, as well, has contradicted 30 years of dogma concerning the use of HRT. Before the publication of the Women's Health Initiative (WHI) Study (7), there was controversy regarding the benefits of such intervention. In general, it was agreed that HRT reduced hot flashes, improved general well-being, and protected bone in peri- and postmenopausal women. Randomized trials have not changed our understanding of these benefits, but virtually all other dogma concerning the use of HRT in healthy women has been turned topsy-turvy.
Before the WHI results, HRT, particularly estrogen, was believed to protect the heart and was widely hypothesized to improve cognition. HRT was believed to be associated with an increased risk of breast cancer, but this was thought to be similar whether progesterone was used or not. Now the WHI results have shown, with the robust methodology of a randomized trial, that estrogen alone does not clearly increase the risk of breast cancer. However, combined use of estrogen and progesterone clearly does. Furthermore, neither estrogen nor the combination of estrogen and progesterone improved cognition, and the combination increased the incidence of stroke and dementia. Coronary artery disease (CAD) was not reduced by the use of estrogen alone, and estrogen plus progesterone increased CAD. Could we have been more wrong?
Unanswered questions remain regarding the role of HRT in women with a previous diagnosis of breast cancer. Might the use of estrogen alone be safer than the use of estrogen combined with a progesterone? Can topical estrogen products such as the Estring or vaginal estrogen creams be used with safety? Additional randomized trials or additional mining of data from completed randomized trials may usefully increase the amount of reliable data. However, one wonders why we took the results of observational studies as seriously as we did.
Why did the observational studies so mislead us? As Holmberg et al. (1) state in their current publication, "it is not surprising that the results from this randomized trial deviate from those in the observational series." The bias inherent in selecting breast cancer survivors for an HRT trial would seem obvious. Every clinician with a patient considering such therapy would be likely to have screened for the presence of undetected metastatic disease. In addition, women at lower risk for recurrence or women who had gone for long periods without recurrence would be more likely to be entered into such case series or observational studies. Attempts to adjust for the effects of these biases were clearly inadequate. It seems ridiculous to continue to impute effects from observational studies when the conduct of a relatively small randomized controlled clinical trial could clearly provide a definitive answer to the question under study.
There are situations in the management of breast cancer that are not amenable to a randomized clinical trial. For example, we rely on observational data to "help" us to advise women who wish to become pregnant following a diagnosis of breast cancer. Basic biology would suggest that pregnancy is risky in women with hormone-responsive disease. We use observational data from women who are clearly highly self- and doctor-selected for pregnancy to suggest that pregnancy is safe or perhaps even advantageous. This approach is methodologically flawed because the selection bias in this situation is probably even greater than in observational studies of the use of HRT in breast cancer survivors. However, we can do little else than use these data, together with an explanation of their potential inadequacies, in advising women because no randomized controlled trial of pregnancy following breast cancer diagnosis will ever be carried out.
In settings such as the HRT controversy, however, randomized trials such as HABITS were long overdue. It is to be hoped that we can learn from this experience to move quickly to interventional studies with robust controlled designs in settings in which observational data clearly have the potential to mislead us.
REFERENCES
1. Holmberg L, Iversen O-E, Rudenstam CM, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J Natl Cancer Inst (2008) 100(7):475–482.
2. Holmberg L, Anderson H. HABITS Steering and Data Monitoring Committees. HABITS (hormonal replacement therapy after breast cancer—is it safe?), a randomized comparison: trial stopped. Lancet (2004) 363(9407):453–455.[CrossRef][ISI][Medline]
3. Col NF, Kim JA, Chlebowski RT. Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res Treat (2005) 7(4):535–540.
4. Marsden J, Sacks NPM. Are randomized trials of HRT in symptomatic women with breast cancer feasible? Fertil Steril (2000) 73(2):292–299.[CrossRef][ISI][Medline]
5. von Schoultz B, Rutqvist LE, Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm Randomized Trial. J Natl Cancer Inst (2005) 97(7):533–535.
6. Chlebowski RT, Col N. Menopausal hormone therapy after breast cancer. Lancet (2004) 363(9407):410–411.[CrossRef][ISI][Medline]
7. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA (2002) 288(3):321–333.
Related Articles in JNCI
CiteULike 
Connotea 
Del.icio.us What's this?
J Natl Cancer Inst 2008 100: 475-482.
J Natl Cancer Inst 2008 100: 447.
This article has been cited by other articles:
|
|
 |
|
  Hormone Therapy in Breast Cancer Survivors Journal Watch (General), April 24, 2008; 2008(424): 2 - 2. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||